近年來，國人的高血糖、高血壓、高血脂的患病率有逐年上升的趨勢。 這三種慢性疾病互相視為共病，並且會顯著增加患心血管疾病的風險。尤其高血脂是心血管疾病的潛在危險因素，而且心血管疾病更是台灣的主要死因之一。本研究透過 Google Scholar, PubMed 和 EMBASE 等資料庫搜索2016年至2021年發行的文獻。本研究會使用Meta-essential整合和綜合不同研究的effect size，使用Revman 5.3軟體進行。本文指出了一些關鍵發現，高血脂併發症的風險並不是特別高，這一點與常見的觀念不同，傳統上人們普遍認為高血脂會導致更高的風險。其次，關於高血脂是否會引發併發症的證據並不一致，雖然過高的血脂會增加罹患心臟病的風險，並可能引發中風、慢性腎衰竭等併發症，但並不是每個高血脂患者都會發展出這些併發症。本研究的結果顯示了高血脂與心血管疾病之間的複雜關係，雖然高血脂增加了心臟疾病的風險，但並非所有高血脂患者都會發展出併發症或面臨較高的死亡風險。只要高血脂患者能夠保持健康的生活方式，如積極運動、戒菸、控制體重、均衡飲食等，他們的預期壽命與膽固醇水平正常的人並無差異。因此，通過調整生活習慣，高血脂患者可以維持與正常人相當的壽命。通過保持健康的生活方式和適當的治療手段，高血脂患者可以延長壽命，並提高生活品質。

The prevalence of hyperglycemia, hypertension, and hyperlipidemia in the compatriots population has increased over the past few years. These three chronic diseases are regarded as comorbidities with each other and significantly increase the risk of developing cardiovascular disease. Hyperlipidemia, in particular, is a potential risk factor for cardiovascular disease, which is one of the leading causes of death in Taiwan. Search through electronic databases like Google Scholar, PubMed, and EMBASE. Searches will be conducted in these databases between 2016 and 2021 in order to identify randomized controlled trials. The meta-essentials will be used for integrating and synthesizing effect sizes from different studies, and Revman 5.3 will be used to perform the meta-analysis. Low-density lipoprotein cholesterol is primarily evaluated as the primary outcome. Patients with hyperlipidemia could be protected from insurance rejection based on the findings of this study.

論文審定書 i
摘要 ii
Abstract iii
Contents iv
Figure contents vi
Table contents vii
Chapter1 - Introduction 1
1.1 Background 1
1.2 Motivation 3
1.3 Purpose 5
Chapter2 - Literature review 6
2.1 Hyperlipidemia 6
2.2 Complications of Hyperlipidemia 10
2.3 Burden of CVD 16
2.4 Decline in cardiovascular disease mortality 20
2.5 LDL-Cholesterol 22
2.6 Meta-analysis 22
Chapter3 - Method 26
3.1 Eligibility criteria 26
3.2 Search strategy 26
3.3 Study selection 27
3.4 Data analysis 27
3.5 Effect size calculate 29
Chapter4 - Result 31
4.1 Selected studies 31
4.2 Effect of type 2 diabetes on hyperlipidemia 41
4.3 Effect of using drugs on hyperlipidemia 43
4.4 Effect of gender on hyperlipidemia 45
Chapter5 - Conclusion 47
5.1 Results of this study 47
5.2 Future suggestions 49
References 51

Aringazina, A., Kuandikov, T., & Arkhipov, V. (2018). Burden of the cardiovascular diseases in central Asia. Central Asian journal of global health, 7(1).
Bhatnagar, P., Wickramasinghe, K., Wilkins, E., & Townsend, N. (2016). Trends in the epidemiology of cardiovascular disease in the UK. Heart, 102(24), 1945-1952.
Braunwald, E. (2021). Cholesterol: the race to the bottom. European Heart Journal, Volume 42, Issue 45, 1 December 2021, Pages 4612–4613.
Braunwald, E. (2022). How to live to 100 before developing clinical coronary artery disease: a suggestion. In: Oxford University Press.
Choi, J. Y., Choi, C. U., Choi, B. G., Park, Y., Kang, D. O., Jang, W. Y., Kim, W., Na, J. O., Kim, J. W., & Kim, E. J. (2021). New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacology and Toxicology, 22, 1-7.
Choudhry, N. K., Isaac, T., Lauffenburger, J. C., Gopalakrishnan, C., Lee, M., Vachon, A., Iliadis, T. L., Hollands, W., Elman, S., & Kraft, J. M. (2018). Effect of a remotely delivered tailored multicomponent approach to enhance medication taking for patients with hyperlipidemia, hypertension, and diabetes: the STIC2IT cluster randomized clinical trial. JAMA internal medicine, 178(9), 1182-1189.
Cohen, J. (2013). Statistical power analysis for the behavioral sciences. Academic press.
Domanski, M. J., Tian, X., Wu, C. O., Reis, J. P., Dey, A. K., Gu, Y., Zhao, L., Bae, S., Liu, K., & Hasan, A. A. (2020). Time course of LDL cholesterol exposure and cardiovascular disease event risk. Journal of the American College of Cardiology, 76(13), 1507-1516.
Fan, D., Li, L., Li, Z., Zhang, Y., Ma, X., Wu, L., & Qin, G. (2018). Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes. Lipids in Health and Disease, 17, 1-7.
Gharios, C., Leblebjian, M., Mora, S., Blumenthal, R. S., Jaffa, M. A., & Refaat, M. M. (2021). The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. Journal of geriatric cardiology: JGC, 18(10), 816.
Haile, K., & Timerga, A. (2020). Dyslipidemia and its associated risk factors among adult type-2 diabetic patients at Jimma University Medical Center, Jimma, Southwest Ethiopia. Diabetes, Metabolic Syndrome and Obesity, 4589-4597.
Hsu, H.-Y., Lin, C.-J., Lee, Y.-S., Wu, T.-H., & Chien, K.-L. (2020). Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis. BMC cardiovascular disorders, 20(1), 1-12.
Karlsson, S. A., Franzén, S., Svensson, A.-M., Miftaraj, M., Eliasson, B., & Andersson Sundell, K. (2018). Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register. BMC Health Services Research, 18, 1-10.
Karlsson, S. A., Hero, C., Svensson, A.-M., Franzén, S., Miftaraj, M., Gudbjörnsdottir, S., Eeg-Olofsson, K., Eliasson, B., & Sundell, K. A. (2018). Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study. BMJ open, 8(3), e020309.
Kaysen, G. A., Ye, X., Raimann, J. G., Wang, Y., Topping, A., Usvyat, L. A., Stuard, S., Canaud, B., van der Sande, F. M., & Kooman, J. P. (2018). Lipid levels are inversely associated with infectious and all-cause mortality: International MONDO study results1. journal of lipid research, 59(8), 1519-1528.
Kılıç, S., Maviş, O., & Böyük, B. (2021). Is Hypomagnesemia a Risk Factor for Atherogenic Dyslipidemia in Patients with Chronic Kidney Disease? CAM AND SAKURA MEDICAL JOURNAL, 1(1), 7-13.
Langer, A., Mancini, G. J., Tan, M., Goodman, S. G., Ahooja, V., Grégoire, J., Lin, P. J., Stone, J. A., & Leiter, L. A. (2021). Treatment inertia in patients with familial hypercholesterolemia. Journal of the American Heart Association, 10(14), e020126.
Lee, Y. H. (2018). An overview of meta-analysis for clinicians. The Korean Journal of Internal Medicine, 33(2), 277.
Lin, C.-F., Chang, Y.-H., Chien, S.-C., Lin, Y.-H., & Yeh, H.-Y. (2018). Epidemiology of dyslipidemia in the Asia Pacific region. International Journal of Gerontology, 12(1), 2-6.
Liu, X., Yu, S., Mao, Z., Li, Y., Zhang, H., Yang, K., Zhang, H., Liu, R., Qian, X., & Li, L. (2018). Dyslipidemia prevalence, awareness, treatment, control, and risk factors in Chinese rural population: the Henan rural cohort study. Lipids in Health and Disease, 17(1), 1-12.
Ma, L.-Y., Chen, W.-W., Gao, R.-L., Liu, L.-S., Zhu, M.-L., Wang, Y.-J., Wu, Z.-S., Li, H.-J., Gu, D.-F., & Yang, Y.-J. (2020). China cardiovascular diseases report 2018: an updated summary. Journal of geriatric cardiology: JGC, 17(1), 1.
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., & Ference, B. A. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal, 41(1), 111-188.
Management, E. R. I. o. Meta-Essentials. https://www.erim.eur.nl/research-support/meta-essentials/
Mensah, G. A., Wei, G. S., Sorlie, P. D., Fine, L. J., Rosenberg, Y., Kaufmann, P. G., Mussolino, M. E., Hsu, L. L., Addou, E., & Engelgau, M. M. (2017). Decline in cardiovascular mortality: possible causes and implications. Circulation research, 120(2), 366-380.
Ministry of Health and Welfare. (2022a). "Control lipid for a joyful heart."(mohw.gov.tw)
Ministry of Health and Welfare. (2022b). Cause of death over the years. https://dep.mohw.gov.tw/DOS/lp-5069-113.html
Narindrarangkura, P., Bosl, W., Rangsin, R., & Hatthachote, P. (2019). Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand. Lipids in Health and Disease, 18, 1-8.
Naser, I. H., Abd Alkareem, Z., & Mosa, A. U. (2021). Hyperlipidemia: pathophysiology, causes, complications, and treatment. A review. kerbala journal of pharmaceutical sciences, 1(19).
Pan, L., Yang, Z., Wu, Y., Yin, R.-X., Liao, Y., Wang, J., Gao, B., Zhang, L., & Group, C. N. S. o. C. K. D. W. (2016). The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 248, 2-9.
Raad, D., Tripathi, P., Cooper, G., & Falck-Ytter, Y. (2016). Role of the cold biopsy technique in diminutive and small colonic polyp removal: a systematic review and meta-analysis. Gastrointestinal endoscopy, 83(3), 508-515.
Raposeiras-Roubin, S., Rosselló, X., Oliva, B., Fernández-Friera, L., Mendiguren, J. M., Andrés, V., Bueno, H., Sanz, J., Martínez de Vega, V., & Abu-Assi, E. (2021). Triglycerides and residual atherosclerotic risk. Journal of the American College of Cardiology, 77(24), 3031-3041.
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M., Langsjoen, P. H., & Mascitelli, L. (2018). LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert review of clinical pharmacology, 11(10), 959-970.
Roth, G. A., Johnson, C. O., Abate, K. H., Abd-Allah, F., Ahmed, M., Alam, K., Alam, T., Alvis-Guzman, N., Ansari, H., & Ärnlöv, J. (2018). The burden of cardiovascular diseases among US states, 1990-2016. JAMA cardiology, 3(5), 375-389.
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., & Benziger, C. P. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American College of Cardiology, 76(25), 2982-3021.
Thomas, H., Diamond, J., Vieco, A., Chaudhuri, S., Shinnar, E., Cromer, S., Perel, P., Mensah, G. A., Narula, J., & Johnson, C. O. (2018). Global atlas of cardiovascular disease. Glob Heart, 13(3), 143-163.
Timmis, A., Townsend, N., Gale, C., Grobbee, R., Maniadakis, N., Flather, M., Wilkins, E., Wright, L., Vos, R., & Bax, J. (2018). European Society of Cardiology: cardiovascular disease statistics 2017. European heart journal, 39(7), 508-579.
Verbeek, R., Hoogeveen, R. M., Langsted, A., Stiekema, L. C., Verweij, S. L., Hovingh, G. K., Wareham, N. J., Khaw, K.-T., Boekholdt, S. M., & Nordestgaard, B. G. (2018). Cardiovascular disease risk associated with elevated lipoprotein (a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. European heart journal, 39(27), 2589-2596.
Wake, M., Oh, A., Onishi, Y., Guelfucci, F., Shimasaki, Y., & Teramoto, T. (2019). Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Atherosclerosis, 282, 19-28.
Wake, M., Onishi, Y., Guelfucci, F., Oh, A., Hiroi, S., Shimasaki, Y., & Teramoto, T. (2018). Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan. Atherosclerosis, 272, 145-152.
Wang, X., He, Y., Wang, T., Li, C., Ma, Z., Zhang, H., Ma, H., & Zhao, H. (2020). Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China. Journal of Cardiovascular Pharmacology and Therapeutics, 25(4), 307-315.
Xia, L., Cheng, L., Jiang, T., Liu, C., Zhang, S., Hu, H., Dai, F., Zhang, Q., & Lu, Y. (2021). Estimation of the prevalence of type 2 diabetes in combination with diabetic kidney disease and identification of the associated factors in patients attending primary hospitals in Anhui Province, China. Journal of International Medical Research, 49(10), 03000605211051225.
Yan, L., Xu, M. T., Yuan, L., Chen, B., Xu, Z. R., Guo, Q. H., Li, Q., Duan, Y., Fu, J. H., & Wang, Y. J. (2016). Prevalence of dyslipidemia and its control in type 2 diabetes: a multicenter study in endocrinology clinics of China. Journal of Clinical Lipidology, 10(1), 150-160.
Yousufuddin, M., Takahashi, P. Y., Major, B., Ahmmad, E., Al-Zubi, H., Peters, J., Doyle, T., Jensen, K., Al Ward, R. Y., & Sharma, U. (2019). Association between hyperlipidemia and mortality after incident acute myocardial infarction or acute decompensated heart failure: a propensity score matched cohort study and a meta-analysis. BMJ open, 9(12), e028638.
Zhang, X., Tang, F., Ji, J., Han, W., & Lu, P. (2019). Risk prediction of dyslipidemia for Chinese Han adults using random Forest survival model. Clinical epidemiology, 1047-1055.